Tech Center 1600 • Art Units: 1649 1675
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17843812 | ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE | Non-Final OA | Genzyme Corporation |
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | Final Rejection | NOVARTIS AG |
| 17775520 | DOSING REGIMEN FOR ANTI-DLL3 AGENTS | Final Rejection | AMGEN INC. |
| 17512751 | Anti-IL-6 Antibody Formulation | Non-Final OA | Novo Nordisk A/S |
| 17711800 | Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific Antibodies | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17629161 | ANTIBODY AGAINST THE OPRF PROTEIN OF PSEUDOMONAS AERUGINOSA, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17755604 | ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS | Final Rejection | MedImmune Limited |
| 17635111 | CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES | Non-Final OA | Regents of the University of Minnesota |
| 18141116 | LYM-1 AND LYM-2 ANTIBODY COMPOSITIONS AND IMPROVED CAR CONSTRUCTS | Non-Final OA | University of Southern California |
| 17616941 | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | Oregon Health & Science University |
| 17798025 | ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF | Final Rejection | Agency for Science, Technology and Research |
| 18020656 | ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18011807 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17257745 | LUCIFERASE VARIANT | Final Rejection | Kikkoman Corporation |
| 18250890 | INTRANASAL IMMUNOTHERAPT FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | Rush University Medical Center |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18028200 | HUMANIZED ANTI-CD22 RECOMBINANT IMMUNOTOXIN AND APPLICATION THEREOF | Non-Final OA | KUNMING SINOWAY NATURAL PHARMACEUTICALS CO., LTD. |
| 17596183 | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof | Non-Final OA | BIOTHEUS INC. |
| 17040851 | GENETICALLY REPROGRAMMED TREGS EXPRESSING MEMBRANE-BOUND IL-10 | Non-Final OA | GAVISH-GALILEE BIO APPLICATIONS LTD. |
| 17796418 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Non-Final OA | Dyne Therapeutics, Inc. |
| 18023913 | ROR1-TARGETING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | HARBOUR BIOMED (SHANGHAI) CO., LTD |
| 17861176 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | Non-Final OA | Bright Peak Therapeutics AG |
| 18002010 | CONDITIONALLY ACTIVE ANTI-CD46 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | Non-Final OA | BIOATLA, INC. |
| 18000533 | AGONIST ANTI-CD40 ANTIBODIES | Non-Final OA | Selvax Pty Ltd |
| 17997583 | ANTIBODIES BINDING IL6R AND USES THEREOF | Non-Final OA | BIOSION INC. |
| 17912091 | BIOMARKER PANELS, SYSTEMS, AND METHODS FOR RISK STRATIFICATION OF A SUBJECT FOR ALZHEIMER'S DISEASE | Non-Final OA | URVOGELBIO PRIVATE LIMITED |
| 17817578 | COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS | Non-Final OA | InvisiShield Technologies Ltd. |
| 17746569 | ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER | Final Rejection | CENTRICSBIO, INC. |
| 17413786 | IL-15 COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | PROVIVA THERAPEUTICS (HONG KONG) LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy